Skip to main content

New Drug Approvals 2012 - Pt. XXIX - Pasireotide diaspartate (SIGNIFOR®)


ATC code: H01CB05
Wikipedia: Pasreotide

On December 14, the FDA approved Pasireotide diaspartate (SIGNIFOR®, Research CodeL SOM-230, CAS# 396091-73-9, Pub-Chem : CID 9941444, KEGG : D10147), a cyclohexide with pharmacologic properties mimicking those of natural hormone Somatostatin for treatment of adult patients with Cushing's disease (CD) for whom pituitary surgery is not an option or has not been curative.

Cushing's disease (CD) is a cause of Cushing's syndrome characterised by increased secretion of ACTH (adrenocorticotropic hormone) from the anterior pituitary. CD is a rare hormone disorder, and  recent statistics indicate that the annual incidence is somewhere between 1 and 10 per million and is 3 times more common in women than in men (from NEMDIS). This is most often as a result of pituitary adenoma or due to excess production of hypothalamus Corticotropin releasing hormone (CRH). More information can be found in Medscape.


The therapeutic activity of Pasireotide diaspartate is through binding to Somatostatin receptors (SSTRs). They belong to GPCR class of targets and there are five known SSTRs in human: SSTR1 (CHEMBL1917P30872), SSTR2 (CHEMBL1804P30874), SSTR3 (CHEMBL2028P32745), SSTR4 (CHEMBL1853P31391) and SSTR5 (CHEMBL1792P35346). These receptor subtypes are expressed in different tissues under normal physiological condition. Corticotroph tumor cells from CD patients frequently over express SSTR5, whereas the other receptor subtypes are often not expressed or expressed at lower levels. Pasireotide diaspartate has a 40-fold increased affinity to SSTR5 than other SSTR analogs binds and activates the receptors resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion.


Since the targets of this drug belong to same family of receptors (somatostatin receptors), multiple  sequence alignment of human SSTR1, 2, 3, 4 and 5 receptors was done using T-coffee which is shown above. The protein sequences (fasta format) of human SSTR1, 2, 3, 4 and 5 can be downloaded from this link here. (courtesy UniProt)


Standard InChI : 1/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1/f/h61,63-67H

Smiles : NCCCC[C@H]1C(N[C@H](C(N[C@H](C(N2[C@H](C(N[C@H](C(N[C@@H](C(N1)=O)CC1=CNC3=CC=CC=C13)=O)C1=CC=CC=C1)=O)C[C@H](C2)OC(NCCN)=O)=O)CC2=CC=CC=C2)=O)CC2=CC=C(C=C2)OCC2=CC=CC=C2)=O
Iupac Name : (2-Aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosuccinic acid] salt


Pasireotide diaspartate is a Somatostatin analog and is cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. The recommended dosage range of Pasireotide diaspartate is 0.3 to 0.9 mg administered as subcutaneous injection twice a day.

Pasireotide diaspartate demonstrates approximately linear pharmacokinetics for a dose range from 0.0025 to 1.5 mg in healthy patients with dose proportional Cmax and AUC and Tmax of 0.25 to 0.5 hrs. Apparent volume of distribution (Vz/F) was >100 L with plasma concentration of about 91%. Plasma protein binding was moderate (88%). It is shown to be metabolically stable in human liver and kidney and is eliminated mainly via hepatic clearance.

Full prescribing information can be found here.

The license holder is Novartis Pharmaceuticals, and the product website is www.signifor.com.

Comments

Popular posts from this blog

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

ChEMBL 29 Released

  We are pleased to announce the release of ChEMBL 29. This version of the database, prepared on 01/07/2021 contains: 2,703,543 compound records 2,105,464 compounds (of which 2,084,724 have mol files) 18,635,916 activities 1,383,553 assays 14,554 targets 81,544 documents Data can be downloaded from the ChEMBL FTP site:   https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_29 .  Please see ChEMBL_29 release notes for full details of all changes in this release: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_29/chembl_29_release_notes.txt New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document IDs CHEMBL4649982-CHEMBL4649998): The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesiz

Julia meets RDKit

Julia is a young programming language that is getting some traction in the scientific community. It is a dynamically typed, memory safe and high performance JIT compiled language that was designed to replace languages such as Matlab, R and Python. We've been keeping an an eye on it for a while but we were missing something... yes, RDKit! Fortunately, Greg very recently added the MinimalLib CFFI interface to the RDKit repertoire. This is nothing else than a C API that makes it very easy to call RDKit from almost any programming language. More information about the MinimalLib is available directly from the source . The existence of this MinimalLib CFFI interface meant that we no longer had an excuse to not give it a go! First, we added a BinaryBuilder recipe for building RDKit's MinimalLib into Julia's Yggdrasil repository (thanks Mosè for reviewing!). The recipe builds and automatically uploads the library to Julia's general package registry. The build currently targe

Identifying relevant compounds in patents

  As you may know, patents can be inherently noisy documents which can make it challenging to extract drug discovery information from them, such as the key targets or compounds being claimed. There are many reasons for this, ranging from deliberate obfuscation through to the long and detailed nature of the documents. For example, a typical small molecule patent may contain extensive background information relating to the target biology and disease area, chemical synthesis information, biological assay protocols and pharmacological measurements (which may refer to endogenous substances, existing therapies, reaction intermediates, reagents and reference compounds), in addition to description of the claimed compounds themselves.  The SureChEMBL system extracts this chemical information from patent documents through recognition of chemical names, conversion of images and extraction of attached files, and allows patents to be searched for chemical structures of interest. However, the curren

New Drug Warnings Browser

As mentioned in the announcement post of  ChEMBL 29 , a new Drug Warnings Browser has been created. This is an updated version of the entity browsers in ChEMBL ( Compounds , Targets , Activities , etc). It contains new features that will be tried out with the Drug Warnings and will be applied to the other entities gradually. The new features of the Drug Warnings Browser are described below. More visible buttons to link to other entities This functionality is already available in the old entity browsers, but the button to use it is not easily recognised. In the new version, the buttons are more visible. By using those buttons, users can see the related activities, compounds, drugs, mechanisms of action and drug indications to the drug warnings selected. The page will take users to the corresponding entity browser with the items related to the ones selected, or to all the items in the dataset if the user didn’t select any. Additionally, the process of creating the join query is no